Drugs / Rivoroxaban
last change Sep 2018 re-read 2 minutes ago

Rivoroxaban

Developed for
cerebral sinovenous thrombosis

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT03191305 Comparator Aug 2017 → Sep 2018 cerebral sinovenous thrombosis Foundation University Islamabad Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Rivoroxaban ClinicalTrials.gov intervention name — accepted as the source's own label NCT03191305
Route Oral “15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.” NCT03191305